

Clinical trials of nadroparin fixed-dose

TrialResults-center www.trialresultscenter.org

1 superficial thrombophlebitis

Trial	Treatments	Patients	Trials design and methods
nadroparin fixed-dose vs nadroparin weight-adjusted			
Vesalio , 2005 n=NA follow-up:	LMWH (nadroparin) body-weight adjusted (full dose for 10 days followed by half dose for 20 additional days) versus nadroparin (2850 anti-Xa IU) for 30 days	patients with superficial vein thrombosis of the great saphenous vein with the thrombosis extending up to 3 cm from the sapheno-femoral junction	

More details and results :

- antithrombotics for superficial thrombophlebitis in superficial thrombophlebitis of the leg at <http://www.trialresultscenter.org/go-Q218>

References

Vesalio, 2005:

Prandoni P, Tormene D, Pesavento R High vs. low doses of low-molecular-weight heparin for the treatment of superficial vein thrombosis of the legs: a double-blind, randomized trial. J Thromb Haemost 2005;3:1152-7 [[15946202](#)]

Entry terms: nadroparin, Nadroparine, Fraxiparin, Fraxiparine, CY 216, CY-216, CY216, LMF CY-216, LMF CY 216, LMF CY216,